Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision‐Making in Systemic Lupus Erythematosus Treatment?

OBJECTIVE: Hydroxychloroquine (HCQ) is a key systemic lupus erythematosus (SLE) drug, making concerns of drug shortages grave. Our objective was to evaluate factors associated with poor outcomes after HCQ taper or discontinuation in SLE. METHODS: We studied 5 Canadian SLE cohorts between 1999 and 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Almeida‐Brasil, Celline C., Pineau, Christian A., Vinet, Evelyne, Hanly, John G., Peschken, Christine A., Clarke, Ann E., Fortin, Paul R., Abrahamowicz, Michal, Bernatsky, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544951/
https://www.ncbi.nlm.nih.gov/pubmed/33369255
http://dx.doi.org/10.1002/acr.24548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544951/
https://www.ncbi.nlm.nih.gov/pubmed/33369255
http://dx.doi.org/10.1002/acr.24548

Ejemplares similares